Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303 Bartlett, Nancy L. , Wilson, Wyndham H. , Jung, Sin-Ho , Hsi, Eric D. ... - - J. Clin. Oncol - 2019 Manuscript - Primary - Primary - Lymphoma - CALGB-50303
Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance) Blum, Kristie A. , Jung, Sin-Ho , Barak, Ian , Hsi, Eric D. ... - ASH - Blood - 2017 Abstract - Primary - Primary - Lymphoma - CALGB-50904
Randomized Trial of Ofatumumab and Bendamustine versus Ofatumumab, Bendamustine and Bortezomib in previously untreated patients with highrisk follicular lymphoma: CALGB 50904 (Alliance) Blum, Kristie A. , Polley, Mei-Yin , Jung, Sin-Ho ... - - Cancer - 2019 Manuscript - Primary - Primary - Lymphoma - CALGB-50904
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Czuczman, Myron S , Porcu, Pierluigi , Johnson, Jeffrey ... - - Leuk. Lymphoma - 2007 Manuscript - Primary - Primary - Lymphoma - CALGB-59901
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study Hsi, Eric D. , Jung, Sin-Ho , Lai, Raymond , Johnson, Jeffrey L. ... - - Leuk. Lymphoma - 2008 Manuscript - Secondary-not-in-original - Primary - Lymphoma - CALGB-59909
Bortezomib Consolidation or Maintenance Following Immunochemotherapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: CALGB/Alliance 50403 Kaplan, Lawrence D. , Maurer, Matthew J. , Stock, Wendy ... - - Am. J. Hematol. - 2020 Manuscript - Primary - Primary - Lymphoma - CALGB-50403
Bortezomib maintenance (BM) or consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): 8-year follow-up of CALGB 50403 (Alliance) Kaplan, Lawrence D. , Maurer, Matthew , Stock, Wendy , Fulton, Noreen ... - ASH - Blood - 2018 Abstract - Primary - Long-Term-Followup - Lymphoma - CALGB-50403
Bortezomib Maintenance (Bm) Versus Consolidation (Bc) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (Asct) For Untreated Mantle Cell Lymphoma (Mcl): CALGB 50403 Kaplan, Lawrence D. , Stock, Wendy , Jung, Sin-Ho , Bartlett, Nancy ... - ASH - Blood - 2015 Abstract - Primary - Primary - Lymphoma - CALGB-50403
High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. Lai, Raymond , Bartlett, Nancy L , Mackey, John R , Jung, Sin-Ho ... - - Leuk. Lymphoma - 2008 Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-59804
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909 Liu, Hongtao , Johnson, Jeffrey L. , Koval, Greg , Malnassy, Greg ... - - Haematologica - 2012 Manuscript - Secondary - Primary - Lymphoma - CALGB-59909
The genetic landscape of mutations in Burkitt lymphoma Love, Cassandra , Sun, Zhen , Jima, Dereje , Li, Guojie , Zhang, Jenny ... - - Nat. Genet. - 2012 Manuscript - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-10002
Diagnosis to treatment interval (DTI) is associated with adverse outcome in newly diagnosed patients with mantle cell lymphoma, a MER/LEO and Alliance collaboration Maurer, Matthew J. , Ruppert, Amy S. , Link, Brian K. ... - ASH - Blood - 2018 Abstract - Primary - Primary - Lymphoma - A151814
Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues Rimm, David L. , Nielsen, Torsten O. , Jewell, Scott D. ... - - J Clin Oncol - 2011 Manuscript - No-Endpoint - Comprehensive - Pathology - C9741 , CALGB-9840
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 clinical trial Schöder, Heiko , Polley, Mei-Yin C. , Knopp, Michael V. ... - - Blood - 2020 Manuscript - Secondary - Primary - Lymphoma - CALGB-50303
High proliferation by the MCL35 assay is associated with inferior outcomes in patients treated with intensive regimens – a correlative study from the Alliance 50403 trial. Scott, David W. , Pitcher, Brandelyn , Liu, Yi Tian , Boyle, Merrill ... - ICML - Hematol Oncol - 2017 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-50403
Interfollicular CD10 Expression and Follicular PD1 Tumor-infiltrating lymphocytes as biologic risk factors in patients with previously untreated follicular lymphoma receiving rituximab-based biologic therapy: An Alliance correlative science study (CALGB 50901, 50402, 50701, 50803, 50401) Sohani, Aliyah R. , Pitcher, Brandy , Chadburn, Amy , Said, Jonathan ... - ASH - Blood - 2015 Abstract - Secondary-not-in-original - Meta-Analysis - Correl Sci NOS - CALGB-50401 , CALGB-50402 , CALGB-50701 , CALGB-50803 , CALGB-50901
Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. Sohani, Aliyah R , Maurer, Matthew J , Giri, Sharmila ... - - Am J Surg Pathol - 2020 Manuscript - Secondary-not-in-original - Meta-Analysis - Correl Sci NOS - CALGB-50402 , CALGB-50701 , CALGB-50803 , CALGB-50901
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET Straus, David J. , Johnson, Jeffrey L. , LaCasce, Ann S. ... - - Blood - 2011 Manuscript - Primary - Primary - Lymphoma - CALGB-50203
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET Straus, David J. , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Blood - 2018 Manuscript - Primary - Primary - Lymphoma - CALGB-50604
